国产rIL-2诱导LAK作实验性抗肿瘤过继免疫治疗

肿瘤细胞体外杀伤实验表明,应用1000u/ml国产重组白细胞介素-2(rL-2)体外诱导6天产生的LAK细胞可获最佳杀伤效果,应用这一诱导条件并参照临床过继性免疫治疗的“3×5”方案,合并IL-2对Balb/c小鼠体内鼠肝癌及裸鼠体内人胃癌移植肿瘤作过继性免疫治疗,生长期肿瘤的总抑瘤率分别达到68.7%和52.4%,表明该剂量的国产rIL-2在实验性抗肿瘤过继免疫治疗中是有效的和安全的。

EXPERIMENTAL IMMUNOTHERAPY OF HUMAN GASTRIC CANCER IN NUDE MICE WITH LYMPHOKINE-ACTIVATED KILLER CELLS INDUCED BY rIL-2

In this study rIL-2 was used to induce mouse spleen cells or human PBMO to transform intoLAKcells at the concentration of 1,000 u/ml in a co-culture system for 6 days, which had been shown in our previous work as the optimal condition to get satisfied anti-tumor effect in vitro, A modified schedule (the 3×5 plan) was developed to assess the effect of the Chinese made rIL-2 on cancer immunotherapy. When the tumors transplanted into mice entered their rapid growing stage on the fifth day after subcutaneous inoculation,rIL-2 was administrated intraperitoneally for 5 days at the dosage of 1,000 u aday for each mouse, followed by another five days during which the rIL-2 was given at the same dosage together with 10 LAK cells. Then the third 'five days' began in which rIL-2 was injected alone again, allowing treatment of the transplanted tumor in vivo for consecutive 15 days. judged by changes of tumor size and weight, the inhibitory indices were 68.7%for mouse liver tumor HAC in Balb/c mice and 52.4%for solid tumor of human,gastric cancer cell line 7901 in nude mouse respectively. It was evident that our adoptive immunotherapy in the above regimen was safe to the tumor-bearing animals and quite effective in suppression of tumor growth.